Tag: non-small cell lung cancer

1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...

1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...

1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...

1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both lobar vs sublobar resections for patients ...

1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent ...

1. Patients who underwent segmentectomy reported a significantly greater 5-year overall survival than those who underwent lobectomy (94.3% vs. 91.1%). ...

1. Patients who underwent segmentectomy reported a significantly greater 5-year overall survival than those who underwent lobectomy (94.3% vs. 91.1%). ...

1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...

1. Almost 30% of patients had an objective response rate, with roughly three-quarters experiencing a reduction in tumour size. 2. ...

Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. Grade 3 ...